Molecular diagnosis of MACC1 status in lung adenocarcinoma by immunohistochemical analysis

Anticancer Research

Volumn 31, Issue 4, 2011, Pages 1141-1145

  Gu, Chundong ^a   Uramoto, Hidetaka ^b   Onitsuka, Takamitsu ^b   Shimokawa, Hidehiko ^b   Iwanami, Takashi ^a   Nakagawa, Makoto ^a   Oyama, Tsunehiro ^b   Tanaka, Fumihiro ^b  

^a DALIAN MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

Adenocarcinoma; Lung cancer; MACC1; Recurrence

Indexed keywords

MESSENGER RNA; METASTASIS ASSOCIATED COLON CANCER 1 PROTEIN; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; GENE OVEREXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN EXPRESSION; UNIVARIATE ANALYSIS;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; POSTOPERATIVE PERIOD; PROGNOSIS; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 79956137735     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Shimokawa H, Uramoto H, Onitsuka T, Chundong G, Ono K, Hanagiri T, Oyama T and Yasumoto K: Overexpression of MACC1 mRNA in lung adenocarcinoma is associated with postoperative recurrence. J Thorac Cardiovasc Surg 141: 895-898, 2011.
2. Minna JD, Roth JA and Gazdor AF: Focus on lung cancer. Cancer Cell 1: 49-52, 2002. (Pubitemid 41039175)
3. Stein U, Walther W, Arlt F, Schwabe H, Smith J, Fichtner I, Birchmeier W and Schlag PM: MACC1, a newly identified key regulator of HGF-MET signaling, predicts colon cancer metastasis. Nat Med 15: 59-67, 2009.
4. Arlt F and Stein U: Colon cancer metastasis: MACC1 and Met as metastatic pacemakers. Int J Biochem Cell Biol 41: 2356-2359, 2009.
5. Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, Postmus PE, Rusch V and Sobin L: The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of Malignant Tumours. J Thorac Oncol 2: 706-714, 2007. (Pubitemid 47357522)
6. Uramoto H, Osaki T, Inoue M, Taga S, Takenoyama M, Hanagiri T, Yoshino I, Nakanishi R, Ichiyoshi Y and Yasumoto K: Fas expression in non-small cell lung cancer: its prognostic effect in completely resected stage III patients. Eur J Cancer 35: 1462-1465, 1999.
7. Yamashita T, Uramoto H, Onitsuka T, Ono K, Baba T, So T, So T, Takenoyama M, Hanagiri T, Oyama T and Yasumoto K: Association between lymphangiogenesis-/ micrometastasis- and adhesion-related molecules in resected stage I NSCLC. Lung Cancer 70(3): 320-328, 2010.
8. Shimokawa H, Uramoto H, Onitsuka T, Iwata T, Nakagawa M, Ono K and Hanagiri T: TS expression predicts postoperative recurrence in adenocarcinoma of the lung. Lung Cancer in press
9. Onitsuka T, Uramoto H, Nose N, Takenoyama M, Hanagiri T, Sugio K, and Yasumoto K: Acquired resistance to gefitinib: The contribution of mechanisms other than the T790M, MET, and HGF status. Lung Cancer 65: 198-203, 2010.
10. Uramoto H, Iwata T, Onitsuka T, Shimokawa H, Hanagiri T and Oyama T: Epithelial-mesenchymal transition in EGFR-TKI-acquired resistant lung adenocarcinoma. Anticancer Res 30: 2513-2517, 2010.
11. Onitsuka T, Uramoto H, Ono K, Takenoyama M, Hanagiri T, Oyama T, Izumi H, Kohno K and Yasumoto K: Comprehensive molecular analyses of lung adenocarcinoma with regard to the epidermal growth factor receptor, K-ras, MET, and hepatocyte growth factor status. J Thorac Oncol 5: 591-596, 2010.
12. Goya T, Asamura H, Yoshimura H, Kato H, Shimokata K, Tsuchiya R, Sohara Y, Miya T and Miyaoka E: The Japanese Joint Committee of Lung Cancer Registry Prognosis of 6644 resected non-small cell lung cancers in Japan: a Japanese lung cancer registry study. Lung Cancer 50: 227-234, 2005. (Pubitemid 41427898)
13. Wakelee HA, Schiller JH and Gandara DR: Current status of adjuvant chemotherapy for stage IB non-small cell lung cancer: implications for the New Intergroup Trial. Clin Lung Cancer 8: 18-21 2006. (Pubitemid 44336239)
14. Kato H, Ichinose Y, Ohta M, Hata E, Tsubota N, Tada H, Tada H, Watanabe Y, Wada H, Tsuboi M, Hamajima N and Ohta M: Japan Lung Cancer Research Group on Postsurgical Adjuvant Chemotherapy. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med 350: 1713-1721, 2004. (Pubitemid 38501140)
15. Rubins J, Unger M and Colice GL: Follow-up and surveillance of the lung cancer patient following curative intent therapy: ACCP evidence-based clinical practice guideline. Chest 132: 355-367, 2007.
16. Müller-Tidow C, Diederichs S, Thomas M and Serve H: Genome-wide screening for prognosis-predicting genes in early-stage non-small-cell lung cancer. Lung Cancer 45: S145-150, 2004.